A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
Hepatocellular Carcinoma (HCC)
DRUG: Brivanib 800 mg, QD|DRUG: Brivanib 400 mg, BID
Disease control rate (DCR) at 3 months from randomization, Defined as the percentage of patients with complete response, partial response, or stable disease at 12 weeks from randomization by RECIST v1.1., 12 weeks from randomization|Time to Progress (TTP), Defined as the time from random assignment to radiologic disease progression., 12 weeks from randomization
Disease control rate (DCR) at 6 months from randomization, Defined as the percentage of patients with complete response, partial response, or stable disease at 24 weeks from randomization by RECIST v1.1., 24 weeks from randomization|Progression-free survival (PFS), Defined as the time from random assignment until the date of disease progression or death as a result of any cause., 24 weeks from randomization|Objective response rate (ORR), Defined as the proportion of randomized patients with CR or PR as the optimal response in each treatment group assessed by use of RECIST 1.1 criteria, 24 weeks from randomization|Overall survival (OS), Refers to the duration from randomization to death from any cause, 24 weeks from randomization
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.